Success Metrics

Clinical Success Rate

77.8%

Based on 7 completed trials

Completion Rate

78%(7/9)

Active Trials

2(10%)

Results Posted

0%(0 trials)

Terminated

2(10%)

Phase Distribution

Ph phase_1

76%

Ph phase_3

Ph phase_2

10%

Ph not_applicable

10%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution21 total trials

Phase 1Safety & dosage

16(76.2%)

Phase 2Efficacy & side effects

2(9.5%)

Phase 3Large-scale testing

1(4.8%)

N/ANon-phased studies

2(9.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

41.2%

7 of 17 finished

Non-Completion Rate

58.8%

10 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(7)

Terminated(10)

Other(1)

Detailed Status

Withdrawn8

Completed7

Terminated2

Recruiting2

Not yet recruiting1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

77.8%

Most Advanced

Phase 3

Trials by Phase

Phase 116 (76.2%)

Phase 22 (9.5%)

Phase 31 (4.8%)

N/A2 (9.5%)

Trials by Status

terminated210%

not_yet_recruiting15%

recruiting210%

unknown15%

completed733%

withdrawn838%

Recent Activity

2 active trials

Showing 5 of 21

completedphase_2

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

NCT01745588

recruitingphase_1

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more

NCT01745588Phase 2

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Completed

NCT06841861Phase 1

Spermatogonial Differentiation Via Testicular Organoid

Recruiting

NCT06564740Not Applicable

Stem Cell Applications in Biliary Atresia Patients

Recruiting

NCT06156241Phase 1

Stem Cell Study for Long COVID-19 Neurological Symptoms

Not Yet Recruiting

NCT02241434Phase 1

Stem Cell Therapy in Duchenne Muscular Dystrophy

Withdrawn

NCT02242071Phase 1

Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Withdrawn

NCT02245711Phase 1

Cell Therapy in Limb Girdle Muscular Dystrophy

Withdrawn

NCT02245698Phase 1

Autologous Stem Cell Therapy in Stroke

Withdrawn

NCT01984814Phase 2

Stem Cell Therapy for Amyotrophic Lateral Sclerosis

Withdrawn

NCT02241928Phase 1

Stem Cell Therapy in Muscular Dystrophy

Withdrawn

NCT02245724Phase 1

Stem Cell Therapy in Mental Retardation

Withdrawn

NCT02245776Phase 1

Stem Cell Therapy in Incurable Neurological Disorders

Withdrawn

NCT00477815Phase 1

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Completed

NCT03264573Not Applicable

Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars

Completed

NCT00349271Phase 3

Cell Therapy in Chagas Cardiomyopathy

Terminated

NCT01751282Phase 1

Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds

Terminated

NCT02372474Phase 1

"It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure